Shadow King

Thyme Care Unveils "Thyme Care Oncology Partners," a Provider-Powered Value-Based Care Model in Partnership with More than 400 Oncologists Nationwide

Retrieved on: 
Wednesday, March 13, 2024
AON, Social, Partnership, Patient, Associate, Cancer, Data, Doctor of Philosophy, Oncology, Workflow, Medicare, CMS, Shadow King, Nursing

Thyme Care will partner with TCOP practices to design and implement value-based care programs for patients covered by participating risk-bearing entities and government-sponsored programs.

Key Points: 
  • Thyme Care will partner with TCOP practices to design and implement value-based care programs for patients covered by participating risk-bearing entities and government-sponsored programs.
  • Thyme Care's comprehensive suite of services empowers oncologists to focus on proactive, patient-centric care, without added administrative or financial overhead.
  • Initiatives like CMS' Enhancing Oncology Model and its 2024 decision to reimburse practices for patient navigation services signal a paradigm shift towards value-based cancer care.
  • "We've long partnered with Thyme Care in New Jersey and with their national expansion, we're excited to see their evolution.

Jasper Health's CARE+ Gets HIPAA Compliant GenAI Upgrade, AskJasper

Retrieved on: 
Monday, October 9, 2023
Multimedia, HL7, HIPAA, Caregiver, Software as a service, Social support, Chief, Cancer, Documentation, Generative, Synthetic media, Clinical trial, Memorial Sloan Kettering Cancer Center, MSK, Jasper, Patient, Quality of life, Medical device, Shadow King

BOISE, Idaho, Oct. 9, 2023 /PRNewswire/ -- Jasper Health, an oncology supportive care and navigation platform, is unveiling AskJasper, an intelligent AI framework during HLTH'23, in Las Vegas. This upgrade provides a new layer of HIPAA compliant, Generative AI-augmented capabilities for its clinician-facing SaaS platform, Care+. Jasper's platform is used by large healthcare institutions including nation-leading Memorial Sloan Kettering Cancer Center (MSK).

Key Points: 
  • This upgrade provides a new layer of HIPAA compliant, Generative AI-augmented capabilities for its clinician-facing SaaS platform, Care+.
  • AskJasper provides a new layer of HIPAA compliant, Generative AI-augmented capabilities for Jasper Care+.
  • Built in an HL7 FHIR standard compliant architecture for bi-directional health data interoperability, AskJasper is available within Care+ or as a service for existing clinical platforms and workflows.
  • Jasper Health is leading the development of a human-centered, empathetic model for tackling critical gaps in cancer care support.

Biofourmis Accelerates and Simplifies Drug Development with Expanded Digital Clinical Trials Solution

Retrieved on: 
Monday, September 18, 2023
Data management, Shadow King, Drug development, AUC, Arrhythmia, Clinical trial, Data collection, Intelligence, Research, Biomarker, QT interval, Documentation, Phlebotomy, Patient, Collection, Patient safety, Risk, Health, Hyperkalemia, Safety, Birth control, Pharmaceutical industry, Medical imaging, Medical device

The solution offers robust digital tools and resources for trial sponsors and investigators aimed at accelerating drug development and improving access and diversity while also reducing costs.

Key Points: 
  • The solution offers robust digital tools and resources for trial sponsors and investigators aimed at accelerating drug development and improving access and diversity while also reducing costs.
  • Biofourmis' Digital Clinical Trials solution includes a technology-enabled, scalable platform and services that support digital tools enablement, trial decentralization, safety monitoring, personalized care, easier participant recruitment and more equitable access to treatment options for patients everywhere.
  • The solution helps sponsors and researchers accelerate clinical development with remote data collection and novel digital endpoints from Biofourmis' library of biomarkers across multiple therapeutic areas.
  • The expanded solution offers a more holistic workflow, new data management automations and a seamless integration of essential clinical trial documentation, participant scheduling and data collection elements.

Lightbeam Health Expands Agreement with Cardinal Health to Advance Enhancing Oncology Model Initiatives

Retrieved on: 
Tuesday, July 11, 2023
Technology, Medical Supplies, Health Technology, Public Policy, Government, Healthcare Reform, Software, General Health, Pharmaceutical, Health, Oncology, Shadow King, Partnership, Doctor of Pharmacy, LCS, OCM, Oncology Care Model, Business, Cardinal, EOM, Experiment (probability theory), Light beam, Research, Social, Cardinal Health, Patient, Axxess Technology Solutions, Artificial intelligence, SVP, Schwind eye tech solutions, Nursing

The Enhancing Oncology Model (EOM) replaced the Oncology Care Model (OCM) in July 2023.

Key Points: 
  • The Enhancing Oncology Model (EOM) replaced the Oncology Care Model (OCM) in July 2023.
  • Through this expanded agreement, Cardinal Health will bolster its EOM offering with Lightbeam’s population health analytics application, Lightbeam Clinical Services (LCS) and Deviceless Remote Patient Monitoring®.
  • “Lightbeam is honored to be Cardinal Health’s trusted partner for population health enablement solutions and capabilities,” says Patrick Burton, SVP of Business Development at Lightbeam Health Solutions.
  • “With its expanded implementation of Lightbeam solutions, Navista™ TS is the all-in-one technology solution for patient-centered oncology care.

Canopy Publishes Research at 2023 American Society of Clinical Oncology Meeting Demonstrating the Impact of ePROs in Identifying Patients at Risk of Early Treatment Discontinuation

Retrieved on: 
Wednesday, May 31, 2023
Shadow King, Data re-identification, IO, American Society of Clinical Oncology, Clinical trial, Lung cancer, Oncology, Research, Immunotherapy, JCO Oncology Practice, ASCO, National Association Medical Staff Services, Journal, MD, Patient, Risk, Identification, Society, Medical imaging, Nursing, Pharmaceutical industry, Canopy

—Michael Kolodziej, MD

Key Points: 
  • —Michael Kolodziej, MD
    The results of the multi-site study of 172 patients were selected for online publication at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois on June 2-6, 2023.
  • The study analyzed reports submitted by lung cancer patients through Canopy's ePRO platform across three community oncology practices.
  • Enable care teams to identify at-risk patients earlier: The presence of early symptoms may indicate a patient population at high risk of early treatment discontinuation.
  • Canopy presented research at the 2022 ASCO Meeting demonstrating up to 45% higher treatment persistence and a 22% reduction in ER visits and hospitalizations for patients utilizing ePROs.

PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS

Retrieved on: 
Wednesday, April 19, 2023
CCP, Learning, Customer success, Communication, Customer support, Head, Cancer, Quality of life, Research, Meta-analysis, Health, HIMSS, App Store (iOS/iPadOS), Women Leaders in Global Health Conference, Patient, Physician, Google Play, Sutter Health, Remote patient monitoring, CDT, RPM, Epic Systems, Conference, NIH, Nursing, Mobile phone, Medical imaging, Shadow King, Veris

NEW YORK, April 19, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), announced that today, Wednesday, April 19, from 11:30 a.m. to 12:30 p.m. CDT, its team will be presenting a comprehensive remote patient monitoring ("RPM") meta-analysis entitled "RPM for Oncology: Bringing the Hospital Home to Improve Lives" at the HIMSS23 Global Health Conference in Chicago. HIMSS is the world's most influential annual health information technology event, with 40,000+ professionals throughout the global health ecosystem in attendance.

Key Points: 
  • HIMSS is the world's most influential annual health information technology event, with 40,000+ professionals throughout the global health ecosystem in attendance.
  • "At Veris, we are deeply committed to enhancing personalized cancer care through RPM using our state-of-the-art Veris Cancer Care Platform, which went live last quarter," said Lishan Aklog, M.D.
  • Veris is a commercial-stage digital health company whose Veris Cancer Care Platform™ (Veris CCP) is designed to enhance personalized cancer care through remote patient monitoring.
  • For oncology practices interested in learning more about the Veris CCP, please visit www.verishealth.com to be contacted by a company representative.

The Evolution and Impact of ePROs in Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, April 17, 2023
Shadow King, University, University Hospitals Birmingham NHS Foundation Trust, Patient, University of Birmingham, TLC, Long, Pharmaceutical industry, Nursing

TORONTO, April 17, 2023 /PRNewswire-PRWeb/ -- This webinar will examine the importance of electronic patient-reported outcomes (ePROs) and how working at pace with methodological rigour led to the development of the Symptom Burden Questionnaire™ (SBQ™), a new ePRO measure which includes 16 symptoms scales, each measuring a different symptom. The featured speakers will also talk about the feasibility trial of non-pharmacological interventions as part of the Therapies for Long COVID (TLC) study.

Key Points: 
  • In this free webinar, learn about the impact of electronic patient-reported outcomes (ePROs) through a unique ePRO measure that is tailored to individual patient needs.
  • Attendees will learn about the evolution of ePROs based on the work at University of Birmingham's Centre for Patient Reported Outcome Research.
  • To avoid increasing health disparities in clinical trials, underserved groups should be included through PRO-specific ethical guidelines for clinical research so that patient-reported outcomes are collected.
  • Register for this webinar to learn about the impact of ePROs through a unique ePRO measure that is tailored to individual patient needs.

LifeOmic Launches Patient Mobile App, Enabling Health Systems and Providers with a Configurable Toolkit to Improve Health Outcomes

Retrieved on: 
Tuesday, April 11, 2023
Shadow King, Education, Health care, Research, Cerner, Attention, HITRUST, Integration, Patient, Collection, GDPR, Growth, Environment, Medical device, Nursing

INDIANAPOLIS, April 11, 2023 /PRNewswire/ -- LifeOmic, a healthcare technology company powering precision health with its end-to-end software solution, the LifeOmic Platform, today announced the launch of its Patient Mobile App. LifeOmic's Patient Mobile App enables a two-way connection between the healthcare team and the patient. With the LifeOmic Patient Mobile App, healthcare providers have access to a highly configurable solution that integrates directly into their existing workflows to meet their unique needs.

Key Points: 
  • LifeOmic's Patient Mobile App enables a two-way connection between the healthcare team and the patient.
  • With the LifeOmic Patient Mobile App, healthcare providers have access to a highly configurable solution that integrates directly into their existing workflows to meet their unique needs.
  • This enables LifeOmic to empower health systems and providers to improve patient outcomes via patient monitoring and reduce readmissions and visits to the emergency department through the valuable insights gained by leveraging patient-reported data.
  • With The LifeOmic Patient Mobile App, health systems and healthcare providers can:
    Deliver multimedia content for extended learning (video, articles, audio, flashcard content)
    Add video conversations; either 1:1 or group sessions.

Leverage Novel Options in Oncology Clinical Trial Design to Reduce Burden For Patients and Sites, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, April 3, 2023
Flo, Knowledge, Shadow King, Science, Pros, PRO, Core, Doctor of Philosophy, Outline, Drug development, BBC, FDA, Medical device, Medical imaging

TORONTO, April 3, 2023 /PRNewswire-PRWeb/ -- The new FDA Patient Focused Drug Development (PFDD) Guidance Series and the Core Patient-Reported Outcomes Measures (PROMs) in Cancer Clinical Trials Guidance demonstrates the industry's commitment to optimizing clinical trial design, presenting the opportunity to minimize participant and site burden. Traditionally, oncology trials have been solely site-based, with lengthy, complex, and burdensome visits. They have also lacked a standard set of PRO domains and can have high levels of missing data.

Key Points: 
  • Attendees will gain insights into what domains should be measured in oncology trials to enable full realization of a treatment's value and facilitate comparison across studies.
  • The featured speaker will discuss the new concept of a modular approach – selecting only the relevant items from an existing instrument – for clinical trials.
  • Attendees will gain an understanding on how PROs can be captured outside clinical settings.
  • Join Flo Mowlem, PhD, Senior Director, eCOA Science & Solutions, Medable, for the live webinar on Monday, April 24, 2023, at 12pm EDT (9am PDT).

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Retrieved on: 
Thursday, March 2, 2023
Hardware, Data Management, Other Health, Technology, Pharmaceutical, General Health, Seniors, Clinical Trials, Science, Biotechnology, Software, Consumer, Other Science, Health, Research, Clinical trial, Drug development, Patient, Doctor of Philosophy, SSI, Organization, MD, Biomarker, Partnership, Medical imaging, Shadow King

Koneksa , the evidence-based digital biomarkers company, announced today an extended partnership with SSI Strategy , a life sciences consulting firm, that will provide both organizations with expanded client service offerings to accelerate and scale the adoption of evidence-based digital biomarkers in clinical trials.

Key Points: 
  • Koneksa , the evidence-based digital biomarkers company, announced today an extended partnership with SSI Strategy , a life sciences consulting firm, that will provide both organizations with expanded client service offerings to accelerate and scale the adoption of evidence-based digital biomarkers in clinical trials.
  • As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development.
  • Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.
  • SSI clients gain access to Koneksa's industry-leading expertise in developing and employing evidence-based digital biomarkers.